Research Article

Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Liuwen Yu,1 Fangmeng Fu,1 Jing Li,1 Meng Huang,2 Bangwei Zeng,3 Yuxiang Lin,1 Qian Mei,1 Jinxing Lv,1 and Chuan Wang1

1Breast Surgery Ward, Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
2Fujian Center for Disease Control and Prevention, Fuzhou, Fujian Province, China
3Nosocomial Infection Control Branch, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China

Correspondence should be addressed to Fangmeng Fu; fufangmengqz@hotmail.com and Chuan Wang; chuanwang1968@outlook.com

Received 11 October 2019; Revised 22 January 2020; Accepted 8 February 2020; Published 16 March 2020

Guest Editor: Cigdem Selli

Copyright © 2020 Liuwen Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Although trastuzumab is the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), drug resistance and disease relapse occur. Therefore, we performed a meta-analysis to assess the efficacy and safety of trastuzumab-containing dual anti-HER2 therapy compared to trastuzumab alone.

Methods. A systematic search was performed to identify eligible randomized controlled trials (RCTs). Main outcomes including event-free survival/invasive disease-free survival (EFS/iDFS), overall survival (OS), and safety were considered.

Results. Ten RCTs were included (15,284 patients). Significant improvements were observed in both EFS/iDFS (HR 0.86, \( p = 0.0003 \)) and OS (HR 0.86, \( p = 0.02 \)) with trastuzumab-based dual anti-HER2 therapy, especially in adjuvant treatment, while in the neoadjuvant setting, dual-targeted therapy also achieved a substantial pathological complete response (pCR) benefit (HR 1.34, \( p = 0.0002 \)). Subgroup analysis revealed that the EFS/iDFS benefit was slightly higher with trastuzumab plus pertuzumab or plus neratinib than trastuzumab plus lapatinib, while OS benefit was significant with trastuzumab plus lapatinib, but there were no subgroup differences (interaction test, \( p = 0.80 \) and 0.24, resp.). In addition, EFS/iDFS benefit was unrelated to hormone receptor status but pronounced in the lymph node-positive (LN+) subgroup, which should be interpreted cautiously for lacking interaction (\( p = 0.18 \)). Besides, patients receiving dual therapy, especially with the lapatinib-containing regimen, experienced more toxicity, but no increase in cardiotoxicity. Conclusions. Despite being associated with more toxicity, trastuzumab-containing dual anti-HER2 therapy is superior to trastuzumab single agent for HER2-positive EBC independent of hormone receptor status. The correlation between survival and LN status needs further verification. Trastuzumab plus pertuzumab or plus neratinib is the preferred regimen with substantial efficacy and lower toxicity.

1. Introduction

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths in women [1]. It is a heterogeneous disease and divided into four major molecular subtypes based on gene expression [2], of which the human epidermal growth factor receptor 2- (HER2-) positive subtype accounts for 15%–20% of breast cancers (BC) and is associated with a worse prognosis [3–5].

HER2 belongs to the human epidermal growth factor receptor (EGFR/HER/ErbB) family which also includes HER1 (EGFR), HER3, and HER4. HER receptors are transmembrane glycoproteins that comprise an extracellular ligand-binding region and an intracellular tyrosine kinase.
domain [6]. Trastuzumab (Herceptin), a monoclonal antibody against subdomain IV of the HER2 extracellular domain (ECD), combined with chemotherapy can significantly improve the prognosis of HER2-positive BC patients compared with chemotherapy alone, which has been demonstrated in the Cochrane meta-analyses [7, 8]. Furthermore, according to several large and long-term follow-up trials, one year of trastuzumab therapy plus chemotherapy has become the standard of care for HER2-positive early breast cancer (EBC) patients [9-12]. However, cases of drug resistance remain and about 30% of patients relapse after trastuzumab therapy and new approaches are required [10-12].

Following trastuzumab, other HER2-targeting agents including lapatinib [13], pertuzumab [14], and neratinib [15] have been approved by the US Food and Drug Administration (FDA) for the treatment of HER2+ BC. Pertuzumab, another humanized monoclonal antibody, differs from trastuzumab in that it binds to the extracellular domain II of HER2 and inhibits homodimer or heterodimer formation, which has complementary mechanisms of action with trastuzumab to improve the efficacy of cancer therapy [16]. Lapatinib and neratinib are both oral, small molecule tyrosine kinase inhibitors that can further enhance HER2 inhibition by blocking intracellular signaling pathways [17]. The difference is that lapatinib is a dual reversible inhibitor of HER1 and HER2 tyrosine kinases, while neratinib is an irreversible inhibitor of HER1, HER2, and HER4.

Further studies focused on identifying biomarkers that may effectively predict which patients will respond best to HER2-targeted therapies. The I-SPY 2 trial, an adaptive phase 2 trial, identifying eight biomarker subtypes with considering HER2 status, hormone receptor status, and risk based on a 70-gene profile, found that neratinib was more likely to have an increased pathological complete response (pCR) rate than trastuzumab when added to standard chemotherapy in patients with HER2-positive (HER2+) and hormone-receptor-negative (HR−) BC [18]. Veeraraghavan et al. found that a clinical subtype in breast cancer with high HER2 amplification and an intact PI3K pathway has a better response to anti-HER2 therapies without chemotherapy [19]. The findings of Kim et al. showed that discordance between IHC-based subtypes and PAM50-based intrinsic subtypes was related to inadequate treatment and diminished survival in BC [20]. Studies also indicated that the percentage of stromal tumor-infiltrating lymphocytes (TILs) was associated with a higher pCR rate and improved survival in patients with HER2+ BC [21-23]. The optimal predictive biomarkers need further validation to contribute to development of precision medicine.

Clinical studies have shown that combining different anti-HER2 agents with complementary mechanisms may overcome drug resistance and be more effective than single-agent therapy. In the neoadjuvant setting, the NeoSphere trial confirmed dual blockade with trastuzumab plus pertuzumab produced a higher pathological complete response (pCR) which was pronounced in the hormone receptor-negative (HR−) patients [24]. The NeoALTTO trial demonstrated trastuzumab plus lapatinib therapy also significantly improved pCR [25]. In the adjuvant setting, the NCCN Guidelines recommended trastuzumab plus pertuzumab as an option for ≥T2 and ≥N1 HER2-positive patients because the APHINITY trial showed a substantial invasive disease-free survival (iDFS) benefit from trastuzumab plus pertuzumab, especially in lymph node-positive (LN+) patients [26, 27]. However, the ALTTO trial reported no substantial DFS benefit from trastuzumab plus lapatinib therapy and there was higher toxicity [28]. The use of dual anti-HER2 therapy and the most beneficial subgroups of patients as well as the correlated toxicities still needs further exploration.

Thus, we conducted a meta-analysis to evaluate the efficacy and safety of using trastuzumab-containing dual anti-HER2 regimens versus standard trastuzumab alone regimen in patients with HER2-positive EBC and to identify the optimal dual anti-HER2 regimens, as well as the subgroup of patients who would most likely benefit from dual therapy.

2. Methods

2.1. Eligibility Criteria. We included prospective phase II/III randomized controlled trials (RCTs) that assessed the efficacy or safety of trastuzumab-containing dual anti-HER2 therapy versus trastuzumab single-agent therapy in patients with HER2-positive EBC. We excluded patients with metastatic BC and studies with insufficient outcomes data.

2.2. Outcome Measures. The primary outcomes were event-free survival/invasive disease-free survival (EFS/iDFS) and overall survival (OS). The secondary outcomes were overall response rate (ORR), pCR rate in breast and axillary LNs, cardiac toxicity, and other toxicities. For definitions of outcomes, see Additional file 1: Appendix 1.

2.3. Search Strategy. We searched Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, and ClinicalTrials.gov for eligible RCTs up to December 2018. We also screened relevant abstracts from the San Antonio Breast Cancer Symposium (SABCS), American Society of Clinical Oncology (ASCO), and European Society for Medical Oncology (ESMO) Meeting as well as related meta-analyses, reviews, and editorials of HER2-positive BC. The following keywords were adopted: breast cancer, trastuzumab (Herceptin), pertuzumab (Perjeta), lapatinib (Tykerb), neratinib (HKI-272), afatinib (BIBW-2992), and MM-111.

2.4. Data Extraction and Quality Assessment. Two authors extracted the data independently and assessed the quality of each trial according to the risk of bias tool of The Cochrane Collaboration [29] and any discrepancies were resolved by consensus or consulting a third author.

2.5. Data Synthesis. We estimated pooled hazard ratios (HRs) for survival outcomes (OS, EFS/iDFS) and risk ratios (RRs) for dichotomous outcomes (ORR, pCR, and toxicities) with 95% confidence intervals (CIs) using the inverse-
variance method of RevMan5.3 software [29]. The random-effects model was adopted to combine heterogeneity across studies.

We used $\chi^2$ and $I^2$ statistics to quantify heterogeneity. Significant heterogeneity existed if $p < 0.10$ or $I^2 > 50\%$. The following subgroup analyses were performed: treatment setting (neoadjuvant or adjuvant setting), dual anti-HER2 regimen (trastuzumab plus lapatinib, trastuzumab plus pertuzumab, or trastuzumab plus neratinib), chemotherapy regimen (taxane-containing non-anthracycline, anthracycline plus taxane, or others), LN status, and hormone receptor status. We carried out sensitivity analyses for main outcomes and those with substantial heterogeneity using the leave-one-out procedure. The impact of small-study and reporting bias was assessed using funnel plots and Begg’s test through Stata/SE 11.2 software [30].

3. Results

3.1. Study Selection and Characteristics. We searched and identified 10 studies corresponding to 16 publications with a total of 15,284 participants for the meta-analysis [24, 28, 31–42]. The flow diagram of study selection is shown in Figure 1. For characteristics of the included studies, see in Table 1. For details, see Additional file 1: Appendix 2.

The median follow-up time varied from 3.8 y to 6.9 y. Seven trials assessed the role of the dual HER2 blockade in a neoadjuvant setting [24, 31–33, 35, 36, 38], while three trials assessed the adjuvant setting [26, 28, 42]. There were seven trials of a trastuzumab plus lapatinib regimen [28, 31–33, 35, 36, 38], two trials considered a trastuzumab plus pertuzumab regimen [24, 26], and one trial considered a trastuzumab plus neratinib regimen [42]. Overall survival of the ExteNET trial was not reported [42]. The “risk of bias” assessment for each trial is shown in the Additional file 1: Appendix 3.

3.2. Effects of Interventions. The forest plots for all outcomes are included in Figure S1 (Additional file 2).

3.2.1. Overall Survival. Four studies reported data about OS for pooling in meta-analyses [26, 28, 31, 36], excluding that by Martin et al. that has not reached the planned 248 events [42]. The pooled OS data demonstrated a statistically significant improvement for patients who received trastuzumab-containing dual anti-HER2 therapy compared to trastuzumab single-agent therapy (HR 0.86, 95% CI 0.75–0.98, $p = 0.02$; Figure 2). There was no heterogeneity across studies ($I^2 = 0\%$, $p = 0.86$).

Subgroup analyses of treatment setting suggested that the survival benefit from the dual HER2 block was on the margins of statistical significance in adjuvant treatment (HR 0.87, 95% CI 0.65–1.00, $p = 0.05$), but no significance in neoadjuvant treatment (HR 0.62, 95% CI 0.35–1.10, $p = 0.10$). No subgroup differences were observed (interaction test, $p = 0.26$). In a subgroup analysis according to type of dual HER2 blockade regimen, the dual therapy with trastuzumab plus lapatinib (HR 0.85, 95% CI 0.73–0.99, $p = 0.03$) significantly improved the OS compared to trastuzumab plus pertuzumab (HR 0.89, 95% CI 0.66–1.19, $p = 0.42$). However, there were no subgroup differences (interaction test, $p = 0.80$).

3.2.2. Event-Free Survival/Invasive Disease-Free Survival. The EFS/iDFS was reported in 5/10 studies [24, 26, 28, 31, 42]. There was a substantial benefit with dual HER2 blocking (HR 0.86, 95% CI 0.79–0.93, $p = 0.0003$; Figure 3) with no heterogeneity among studies ($I^2 = 0\%$, $p = 0.57$).

Subgroup analyses of treatment setting indicated a substantial EFS/iDFS benefit with dual blockade in an adjuvant setting (HR 0.86, 95% CI 0.78–0.94, $p = 0.001$) versus the neoadjuvant setting (HR 0.75, 95% CI 0.49–1.13, $p = 0.17$), but no subgroup difference (interaction test, $p = 0.52$). In a subgroup analysis according to type of dual anti-HER2 regimen, higher EFS/iDFS benefits were observed in the regimens with trastuzumab plus neratinib (HR 0.73, 95% CI 0.58–0.93, $p = 0.01$; Figure 4) and trastuzumab plus pertuzumab (HR 0.80, 95% CI 0.65–0.98, $p = 0.03$; Figure 4) than trastuzumab plus lapatinib (HR 0.90, 95% CI 0.81–0.99, $p = 0.03$; Figure 4). However, no subgroup differences were found (interaction test, $p = 0.24$).

Furthermore, we also found that the benefit of EFS/iDFS with a dual HER2 block in the LN+ subgroup (HR 0.75, 95% CI 0.63–0.88, $p = 0.0005$; Figure 5(a)) was superior to the LN-subgroup (HR 1.01, 95% CI 0.67–1.53, $p = 0.95$; Figure 5(a)) but was not associated with the hormone receptor status (Figure 5(b)). However, the interaction test suggested that the EFS/iDFS benefit does not depend on LN status ($p = 0.18$).

3.2.3. Overall Response Rate. The ORR data from five studies were analyzed [24, 25, 35, 36, 38]. We excluded Guarnieri et al. [33] in which the clinical objective response was reported as approximately 90% without further information. The difference in ORR did not reach statistical significance in either the pooled analysis (RR 1.03, 95% CI 0.96–1.10, $p = 0.45$) or the subgroup analysis of the dual anti-HER2 regimen.

3.2.4. Pathological Complete Response. Seven neoadjuvant studies reported pCR data [24, 31–33, 35, 36, 38]. The pCR rates for the dual-targeted group and monotherapy group were 51.60% and 38.26%. There was a significant 13.34% absolute improvement (RR 1.34, 95% CI 1.15–1.57, $p = 0.0002$) with no substantial heterogeneity ($I^2 = 34\%$, $p = 0.17$).

Subgroup analyses of dual anti-HER2 regimens showed a pCR rate favouring the regimen of trastuzumab plus pertuzumab (RR 1.83, 95% CI 1.19–2.81, $p = 0.006$) versus trastuzumab plus lapatinib (RR 1.29, 95% CI 1.06–1.56, $p = 0.003$). A similar benefit was found in the HR– subgroup (RR 1.29, 95% CI 1.06–1.56, $p = 0.01$) rather than the HR+ subgroup (RR 1.12, 95% CI 0.92–1.37, $p = 0.25$) in the subgroup analysis of hormone receptor status. However,
3.3. Safety. The forest plots for all outcomes are included in Figure S1 (Additional file 2).

3.3.1. Cardiac Toxicities. Eight studies assessing cardiotoxicity were pooled in the meta-analysis [24–26, 28, 32, 33, 36, 38]. There was no significant difference in cardiotoxicity between trastuzumab-containing dual-targeting therapy and trastuzumab alone therapy (RR 1.14, 95% CI 0.63–2.05, \( p < 0.66 \), Figure 6).

In the subgroup analysis of a treatment setting, no significant cardiotoxicity was observed either in the neo-adjuvant setting (RR 0.92, \( p = 0.88 \)) or in the adjuvant setting (RR 1.38, \( p = 0.51 \)). Subgroup analysis stratified by congestive heart failure (CHF) and left ventricular ejection fraction (LVEF) decline showed no substantial increase in CHF (RR 0.45, \( p = 0.28 \)) and LVEF decline (RR 0.95, \( p = 0.31 \)) in patients receiving dual-targeting therapy. Moreover, we performed subgroup analyses for CHF and LVEF, stratified by the type of dual anti-HER2 regimen and the type of chemotherapy, and no statistical difference was observed. In our meta-analysis, LVEF decline was defined as reported by the authors of included studies because different thresholds were used. More events in the APHINITY and ALTTO trials may be due to the fact that large enrolled population and broad definition of LVEF decline were used, so we also performed the corresponding analyses using the narrow definition of LVEF decline and the results also showed no significant statistical difference.

3.3.2. Other Toxicities. We conducted analyses of other common grade 3/4 toxicities reported in more than half of the trials: diarrhea (10 studies), hepatic toxicity (9 studies), skin disorder (9 studies), neutropenia (8 studies), febrile neutropenia (7 studies), nausea and vomiting (5 studies), and fatigue (5 studies).

Patients receiving dual HER2 blocking therapy had a significant increase in the incidence of grade 3/4 diarrhea (RR 8.22, 95% CI 3.89–17.38, \( p < 0.00001 \)), hepatic toxicity (RR 2.32, 95% CI 1.30–4.14, \( p = 0.004 \)), skin disorder (RR 4.20, 95% CI 2.40–7.34, \( p < 0.00001 \)), and nausea and vomiting (RR 3.51, 95% CI 1.19–10.38, \( p = 0.02 \)). There were no statistical differences in the incidence of neutropenia, febrile neutropenia, or fatigue.

Subgroup analysis of dual anti-HER2 regimens and chemotherapy regimens was performed for each toxicity, the results showed that diarrhea was mainly associated with the trastuzumab plus neratinib group and trastuzumab plus lapatinib group, and hepatic toxicity and skin disorders were mainly associated with the trastuzumab plus lapatinib group, while nausea and vomiting were associated with the trastuzumab plus neratinib group. And a taxane-containing non-anthracycline regimen has a lower risk of diarrhea than an anthracycline plus taxane regimen. No other differences were observed in the subgroup analyses.

3.4. Sensitivity Analyses and Publication Bias. As most of the outcomes did not show significant heterogeneity, we carried out sensitivity analyses for OS, EFS/iDFS, ORR, pCR, and cardiac toxicity and the results were stable (Additional file 2: Figure S2). The funnel plots and Begg's test for OS and EFS/iDFS indicated no evidence of publication bias (Additional file 2: Figure S3).
### Table 1: Characteristics of the included studies.

| Study                  | Neoadjuvant setting | Adjuvant setting | Phase | N  | MF | Chemotherapy (wks) | Anti-HER2 therapy | Chemotherapy (wks) | Anti-HER2 therapy | Arms | LN+ patients (%) | HR+ patients (%) | Duration* (wks) | Outcomes                                      |
|------------------------|--------------------|------------------|-------|----|----|-------------------|-------------------|-------------------|-------------------|------|-----------------|-----------------|----------------|----------------------------------------------|
| **Adjuvant setting**   |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| ExteNET*               | IIi                | 3840             | 5.2 y | UNK| None| T or none         | UNK               | UNK               | T+N               | 1420 | 1085 (76)       | 816 (57)        | 52              | DFS, IDFS, OS, and safety                     |
| (Martin1 2017;         |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| Martin2 2017; Chan     |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| ALTTO*                 | III                | 8381             | 6.9 y | UNK| None| None              | Design 1:         | Design 2: A×(9–12) + Taxane×12 | Design 2B: (Doc + Carb)×18 | T   | 2093            | 1080 (52)       | 1203 (57)       | DFS, OS, and safety                               |
| (Piccart-Gebhart       |                    |                  |       |    |    | chemotherapy×(12–18) | T+L               | T→L               | 2091             | 1078 (52) | 1205 (58) | T12→L34                          |                               |
| 2016; Moreno-Aspitia1  |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| 2017b; Moreno-Aspitia2 |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| APHINITY (Von Minckwitz| III                | 4805             | 3.8 y | None| None| None              | FEC×(9–12) + Doc/ Pal×12; or AC/ EC×(8–12) + Doc/Pal×12; or (Doc + Carb)×18 | T+P               | 2400 | 1503 (63)       | 1536 (64)       | 52              | IDFS, DFS, OS, and safety                     |
| 2017)                 |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| **Neoadjuvant setting**|                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| EORTC 10054            | IIb                | 128              | NR    | Doc×9 + FEC×9     | L + T | NR          | T      | 52               | 33 (64)        | 25 (48)       | 9               | pCR (breast + nodes), pCR (breast), response rates, and safety |
| (Bonnefoi 2014)        |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| CALGB 40601            | III                | 295              | NR    | wP×16 | L + T | AC×(8–12)       | T      | 117              | 69 (59)       | 16             | pCR (breast + nodes) and safety                 |
| (Carey 2016)           |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| NeoALTTO*              | III                | 455              | 3.84 y| wP×12w | L + T | FEC×9             | T + L             | 152              | UNK             | 77 (51)       | 52              | pCR (breast + nodes) and clinical objective responses |
| (Baselga 2012; de      |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| Azambuja 2014)         |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| CHER-LOB*              | IIb                | 121              | NR    | wP×12 + FEC×12    | L + T | NR          | T      | 46               | 28 (61)       | 26             | pCR (breast + nodes) and clinical objective responses |
| ( Guarneri 2012;       |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| Guarneri 2015)         |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| NeoSphere*             | II                 | 417              | 5 y   | D×12 | T + P | FEC×9             | T                 | 107              | 75 (70)       | 50 (47)       | 12              | pCR (breast) and pCR (breast + nodes) Clinical response rate, safety, DFS, FFS, and OS |
| (Gianni 2012; Gianni    |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| 2016)                 |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| LPT109096              | II                 | 100              | NR    | FEC×12 + wP×12    | T + L | UNK             | UNK               | 33               | 20 (61)       | 20 (61)       | 26              | pCR (breast + nodes), clinical complete response (CCR), and safety |
| (Holmes 2013)          |                    |                  |       |    |    |                   |                   |                   |                   |      |                 |                 |                |                               |
| Study          | Phase | N   | MF | Neoadjuvant treatment | Adjuvant treatment |
|---------------|-------|-----|----|-----------------------|--------------------|
|               |       |     |    | Chemotherapy (wks)    | Anti-HER2 therapy |
|               |       |     |    |                       | Chemotherapy (wks) |
|               |       |     |    |                       | Anti-HER2 therapy |
|               |       |     |    |                       | Arms (%)          |
|               |       |     |    |                       | LN+ patients (%)  |
|               |       |     |    |                       | HR+ patients (%)  |
|               |       |     |    |                       | Duration (wks)    |
|               |       |     |    |                       | Outcomes           |
| NSABP B-41*   | III   | 519 | 5y | AC × 12 + wP × 12     | T + L              |
|               |       |     |    | None                  | T                  |
|               |       |     |    |                       | 174                |
|               |       |     |    |                       | 85 (49)            |
|               |       |     |    |                       | 108 (62)           |
|               |       |     |    |                       | 12                 |
|               |       |     |    |                       | pCR (breast), pCR  |
|               |       |     |    |                       | (breast + nodes),  |
|               |       |     |    |                       | clinical           |
|               |       |     |    |                       | complete response, |
|               |       |     |    |                       | safety,            |
|               |       |     |    |                       | and OS             |
| (Robidoux 2013; |       |     |    |                       |                    |
| Robidoux 2016) |       |     |    |                       |                    |

MF: median follow-up; A: anthracycline; FEC: fluorouracil + epirubicin + cyclophosphamide; Doc: docetaxel; Carb: carboplatin; Pal: paclitaxel; wP: weekly paclitaxel; wk: week; HR+: hormone receptor positive; LN+: lymph node positive; T: trastuzumab; L: lapatinib; P: pertuzumab; N: neratinib; T + L: trastuzumab plus lapatinib; T → L: trastuzumab followed by lapatinib; NR: unreported; UNK: unknown. *Duration of dual anti-HER2 therapy. *Studies with more than one publication. # In the ExteNET trial (Martin 2017), lymph node- (LN-) positive patients were divided into two subgroups, 1–3 positive LN (Martin 2017) and ≥ 4 positive LN (Martin 2017), for the subgroup analysis of LN status. In the ALTTO trial (Moreno-Aspitia 2017), there were two experimental groups (trastuzumab plus lapatinib group (Moreno-Aspitia 2017) and trastuzumab followed by lapatinib group (Moreno-Aspitia 2017).
4. Discussion

This meta-analysis of RCTs demonstrated that trastuzumab-containing dual anti-HER2 therapy was superior to standard trastuzumab alone therapy for HER2-positive EBC treatment, with a significant improvement in EFS/iDFS and OS.

Although dual anti-HER2 therapy has shown significant improvement in pCR in neoadjuvant treatment, our results demonstrated that the benefit of dual-targeting therapy in the neoadjuvant treatment did not extend to the long-term survival benefits, a significant DFS and OS benefit in favour of the adjuvant treatment versus the neoadjuvant treatment. Despite no substantial heterogeneity was found in all pooled analyses, differences between studies might be relevant. Firstly, differences in duration of dual-targeted treatment are as follows: all three studies included in the adjuvant setting have completed a 1-year dual anti-HER2 therapy [26, 28, 42], while there was only one of seven studies in the neoadjuvant setting [31]. Secondly, differences in included populations are as follows: in the adjuvant treatment, the population recruited in the APINITY trial and the ExteNET trial were relatively high-risk (with more LN+ patients, 63% and 77%, resp.), which were more likely to report positive results in the adjuvant setting. However, no interaction between survival and treatment setting was observed (interaction test for EFS/iDFS and OS, \( p = 0.52 \) and 0.26). Thus, some caution is still required.

When taking hormone receptor status into consideration, several meta-analyses of neoadjuvant treatment demonstrated that the pCR rate was significantly improved in patients receiving dual HER2 block versus trastuzumab alone and higher in HR patients [43–46]. In adjuvant therapy, the APINITY and ALTTO trials suggested that the dual-targeted therapy could significantly enhance EFS/iDFS in HR patients [26, 28]. These results of previous studies seem to indicate that HR patients can benefit more from dual anti-HER2 therapy. Nonetheless, subgroup analysis of hormone receptor status in our meta-analysis found no difference in EFS/iDFS between the two groups. Even if the pCR was more pronounced in HR patients, no interaction was found (interaction test, \( p = 0.34 \)). Therefore, hormone receptor status may not be a determinant of a dual-targeted selective therapy. Or as described in the CALGB 40601 study, we should pay more attention to the subtype than hormone receptor status when predicting pCR [32]. Of note, the ExteNET trial suggested that neratinib administered after...
trastuzumab significantly improved iDFS in hormone receptor-positive (HR+) patients with HER2-positive BC. This may be a consequence of there being no cross-resistance for neratinib and trastuzumab in the HR+ patients, or the interaction of neratinib with hormones reversed the upregulation of estrogen receptors caused by trastuzumab to modify HER2 resistance [42]. With results diametrically opposite to other studies, we conducted an extra subgroup analysis excluding the ExteNET study and the results did not change.

The LN status, another important factor affecting the clinical treatment decisions, has been shown in clinical studies that LN+ patients are more likely to benefit from dual-targeting therapy [24, 42], but our results suggested that, despite the more pronounced EFS/iDFS benefit in LN+ patients, there was no significant interaction between survival and LN status \( (p = 0.18) \). Similarly, a recent meta-analysis assessing the optimal duration of trastuzumab treatment also showed no significant interaction between survival and HR status or LN status \( (p = 0.30, f = 0.24) \) [47]. The guidelines recommend using an interaction test for subgroup analyses, as evidenced that inappropriate subgroup-specific analysis was of low reliability and the problem may be underestimated [48]. Thus, the subgroup results should be interpreted carefully.

In addition to the above, different combination regimens of dual HER2 block might affect efficacy. Subgroup analysis of the type of dual anti-HER2 regimen revealed that OS was significantly improved with trastuzumab plus lapatinib, while the effect on EFS/iDFS did not differ significantly among the three groups. Although the OS benefit with trastuzumab plus lapatinib might be somewhat unexpected considering the negative results of the ALTTO trial, the following points in the ALTTO trial should be noted, except for the unreported final OS results of the ExteNET trial: First, the recruited patients were designed for DFS, with a low risk of recurrence (more LN− (40%) and HR+ (57%) patients than the other included trials), which may explain the lower-than-expected DFS event [40]. Second, a time-driven analysis was conducted to obtain early results rather than a more mature event-driven analysis [49]. Third, due to the toxicity of lapatinib, the lapatinib group was closed early and the proportion of patients who completed the planned dose in the dual-targeting group was lower. Finally, studies demonstrated that intermittent administration of lapatinib is more effective than continuous administration [50, 51]. All of above may affect statistical power and result in negative results [49, 52]. Notably, in the ALTTO trial, a protocol modification required \( p \leq 0.25 \) because of the early closure of the lapatinib group, while we considered \( p \leq 0.05 \) to be
| Study or subgroup | Log [hazard ratio] | SE | Weight (%) | Hazards ratio IV, random, 95% CI | Hazards ratio IV, random, 95% CI |
|------------------|-------------------|----|------------|----------------------------------|----------------------------------|
| 1.8.1 LN+        |                   |    |            |                                  |                                  |
| Martin1 2017     | –0.29             | 0.18| 18.9       | 0.75 [0.53, 1.06]                |                                  |
| Martin2 2017     | –0.4              | 0.19| 16.9       | 0.67 [0.46, 0.97]                |                                  |
| von Minckwitz 2017 | –0.26             | 0.11| 50.5       | 0.77 [0.62, 0.96]                |                                  |
| Subtotal (95% CI)|                   |    |            | 86.3                             | 0.75 [0.63, 0.88]                |
|                  |                   |    |            | Heterogeneity: tau² = 0.00; chi² = 0.41; df = 2 (P = 0.82); I² = 0% | Test for overall effect: Z = 3.49 (P = 0.0005) |
| 1.8.2 LN−        |                   |    |            |                                  |                                  |
| Martin 2017      | –0.19             | 0.36| 4.7        | 0.83 [0.41, 1.67]                |                                  |
| von Minckwitz 2017 | 0.12              | 0.26| 9.0        | 1.13 [0.68, 1.88]                |                                  |
| Subtotal (95% CI)|                   |    |            | 13.7                             | 1.01 [0.67, 1.53]                |
|                  |                   |    |            | Heterogeneity: tau² = 0.00; chi² = 0.49; df = 1 (P = 0.49); I² = 0% | Test for overall effect: Z = 0.07 (P = 0.95) |
|                  |                   |    |            |                                  |                                  |
| Total (95% CI)   |                   |    |            | 100.0                            | 0.78 [0.67, 0.91]                |
|                  |                   |    |            | Heterogeneity: tau² = 0.00; chi² = 2.73; df = 4 (P = 0.60); I² = 0% | Test for overall effect: Z = 3.22 (P = 0.001) |
|                  |                   |    |            |                                  | Test for subgroup differences: chi² = 1.84; df = 1 (P = 0.18); I² = 45.6% |

(a)

(b) Figure 5: Subgroup analyses of event-free survival/invasive disease-free survival (EFS/iDFS). (a) EFS/iDFS stratified by lymph node status. LN+: lymph node positive; LN−: lymph node negative; Martin1 2017: subgroup of 1–3 positive LN; Martin2 2017: subgroup of ≥ 4 positive LN. (b) EFS/iDFS stratified by hormone receptor status. HR+: hormone receptor positive; HR−: hormone receptor negative; IV: inverse-variance method; random: random-effects model; Moreno-Aspitia1 2017: trastuzumab plus lapatinib group; Moreno-Aspitia2 2017: trastuzumab followed by lapatinib group.
Table: Cardiac toxicity of trastuzumab-containing dual anti-HER2 therapy—all studies. IV: inverse-variance method; random: random-effects model.

| Study or subgroup | Dual blockade | Control | Weight (%) | Risk ratio IV, random, 95% CI | Risk ratio IV, random, 95% CI |
|------------------|---------------|---------|------------|-------------------------------|-------------------------------|
| Baselga 2012     | 1             | 152     | 149        | 4.1                           | 0.98 [0.06, 15.53]           |
| Bonnefoi 2014    | 3             | 50      | 0          | 53                            | 7.41 [0.39, 139.97]          |
| Carey 2016       | 4             | 173     | 7          | 107                           | 1.01 [0.26, 3.94]            |
| Gianni 2012      | 3             | 107     | 1          | 107                           | 3.00 [0.32, 28.39]           |
| Guarneri 2012    | 0             | 46      | 1          | 36                            | 0.26 [0.01, 6.26]            |
| Piccart-Gebhart 2016 | 972    | 4137    | 518        | 2076                          | 0.94 [0.86, 1.03]            |
| Robidoux 2013    | 1             | 173     | 7          | 178                           | 0.15 [0.02, 1.18]            |
| von Minckwitz 2017 | 15         | 2364    | 6          | 2405                          | 2.54 [0.99, 6.54]            |

Total (95% CI) | 7146 | 5122 | 100.0 | 1.14 [0.63, 2.05] |

Heterogeneity: $\tau^2 = 0.21; \chi^2 = 10.81; df = 7 (P = 0.15); I^2 = 35\%$

Test for overall effect: $Z = 0.44 (P = 0.66)$

Figure 6: Cardiac toxicity of trastuzumab-containing dual anti-HER2 therapy—all studies. IV: inverse-variance method; random: random-effects model.

Regardless of the risk of cardiac toxicity did not increase, as described in other meta-analyses [43, 45, 46], which increases our confidence in using dual-targeted therapy. However, the incidence of grade 3/4 diarrhea, hepatic toxicity, nausea and vomiting, and skin disorders was significantly increased. Subgroup analysis of dual anti-HER2 regimen showed that the toxicities in the lapatinib group were mainly diarrhea, hepatic toxicity, and skin disorders, and the main toxicities for the neratinib group were diarrhea, nausea and vomiting, and fatigue, while for the pertuzumab group the main toxicity was diarrhea. Almost all trials that contained treatment with lapatinib reported a dose reduction, termination of treatment, and even early closure of the treatment group due to the high risk of adverse events (AEs) that can also be seen in other published meta-analyses [45, 54, 55]. Conversely, most of the cases of diarrhea reported in the neratinib-containing group were of low grade and were preventable and tolerable despite the high incidence. The risk of AEs in the pertuzumab-containing group was significantly lower than that in the lapatinib group and the neratinib group. Therefore, we believe that trastuzumab plus lapatinib would be the most effective regimen if the patients could tolerate the toxicity. If they cannot, then trastuzumab plus pertuzumab or plus neratinib would be the preferred options for HER2-positive EBC after weighing the effects and safety. We are still waiting for the final OS result of the ExteNET trial and more trials using dual HER2 blocking with trastuzumab plus pertuzumab or plus neratinib.

Our manuscripts collected comprehensive and latest clinical data to make up for the deficiencies of previous studies and present the most cutting-edge results in this field. We compared dual anti-HER2 therapy with the current standard care (trastuzumab alone) for treating HER2-positive EBC and comprehensively evaluated efficacy and safety, the neoadjuvant and adjuvant setting, and corresponding subgroup analyses to look for the populations that would most benefit to identify crucial personalize therapy.

Nevertheless, shortcomings remain. Firstly, the heterogeneous nature of the patients, the clinical settings, and the drugs in this meta-analysis may reduce reliability. However, we conducted the pooled analyses, several correlation subgroup analyses, and sensitivity analyses, and the results did not show any significant heterogeneity. Secondly, for data available for the regimen with trastuzumab plus neratinib or plus pertuzumab, hormone receptor status and LN status were limited. And neratinib was administered after completion of trastuzumab-based adjuvant therapy rather than being used simultaneously in the ExteNET trial; further RCTs are still needed to focus on trastuzumab plus pertuzumab or plus neratinib regimens and LN status and hormone receptor status to improve our understanding. Finally, EFS/iDFS and OS can be affected by subsequent adjuvant therapy such as the regimens and duration of treatment.

5. Conclusions

We conclude that the trastuzumab-containing dual HER2 block is superior to standard trastuzumab alone for patients...
with HER2-positive EBC. Although the dual HER2 block was associated with a higher risk of grade 3/4 AEs, especially in the lapatinib group, there was no increase in cardiotoxicity. Trastuzumab combined with lapatinib achieved the greatest OS benefit but is accompanied by higher AEs. Weighing the pros and cons, trastuzumab plus pertuzumab or plus neratinib is the preferred choice with substantial benefit and lower toxicity, a result still waiting for the final OS results of the ExteNET trial. Notably, the survival was independent of hormone receptor status, and the correlation between survival and LN status should be interpreted cautiously. Further investigations are needed to determine the best dual antiHER2 regimen and the subgroup populations that will benefit most.

Data Availability

The data used to support the findings of this study are included within the supplementary information files.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Liuwen Yu, Fangmeng Fu, and Jing Li were involved in the conception and design of the study. Liuwen Yu, Fangmeng Fu, Jing Li, Yuxiang Lin, Qian Mei, and Jinxing Lv participated in the study search, selection, and evaluation. Liuwen Yu, Bangwei Zeng, Meng Huang, and Jing Li performed data extraction and analysis. Liuwen Yu drafted the manuscript, and all authors participated in the writing of the manuscript and interpretation of the results. All authors read and approved the final version.

Supplementary Materials

Additional file 1: Appendix 1: definitions of outcomes. Appendix 2: characteristics of included studies. Appendix 3: risk of bias assessment. Additional file 2: Figure S1: forest plots for all outcomes. Figure S2: sensitivity analyses. Figure S3: publication bias. (Supplementary Materials)

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] C. M. Perou, T. Sorlie, M. B. Eisen et al., "Molecular portraits of human breast tumors," Nature, vol. 406, no. 6797, pp. 747–752, 2000.

[3] D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, and W. McGuire, "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene," Science, vol. 235, no. 4878, pp. 177–182, 1987.

[4] D. Slamon, W. Godolphin, L. Jones et al., "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer," Science, vol. 244, no. 4905, pp. 707–712, 1989.

[5] T. Sorlie, C. M. Perou, R. Tibshirani et al., "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications," Proceedings of the National Academy of Sciences, vol. 98, no. 19, pp. 10869–10874, 2001.

[6] M. A. Olavejoye, R. M. Neve, H. A. Lane, and N. E. Hynes, "New EMBO members’ review: the ErbB signaling network: receptor heterodimerization in development and cancer," The EMBO Journal, vol. 19, no. 13, pp. 3159–3167, 2000.

[7] S. Balduzzi, S. Mantarro, V. Guarnieri et al., "Trastuzumab-containing regimens for metastatic breast cancer," Cochrane Database of Systematic Reviews, vol. 6, 2014.

[8] L. Moja, L. Tagliabac, S. Balduzzi et al., "Trastuzumab containing regimens for early breast cancer," Cochrane Database of Systematic Reviews, vol. 4, 2012.

[9] P. Conte, A. Frassoldat, G. Bisagni et al., "9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study," Journal of Clinical Oncology, vol. 35, 2018.

[10] D. J. Slamon, W. Eiermann, N. J. Robert et al., "Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC—>T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC—>TH) with doxetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer," Cancer Research, vol. 76, no. 4, Article ID S5-04-S5-04, 2016.

[11] D. Cameron, M. J. Piccarg-Behart, R. D. Gelber et al., "11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial," The Lancet, vol. 389, no. 10075, pp. 1195–1205, 2017.

[12] E. A. Perez, E. H. Romond, V. J. Suman et al., "Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831," Journal of Clinical Oncology, vol. 32, no. 33, pp. 3744–3752, 2014.

[13] Q. Ryan, A. Ibrahim, M. H. Cohen et al., "FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2," The Oncologist, vol. 13, no. 10, pp. 1114–1119, 2008.

[14] L. Amiri-Kordestani, S. Wedam, L. Zhang et al., "First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer," Clinical Cancer Research, vol. 20, no. 21, pp. 5359–5364, 2014.

[15] H. Singh, A. J. Walker, L. Amiri-Kordestani et al., "U.S. food and drug administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer," Clinical Cancer Research, vol. 24, no. 15, pp. 3486–3491, 2018.

[16] C. W. Adams, D. E. Allison, K. Fiala et al., "Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab," Cancer Immunology, Immunotherapy, vol. 55, no. 6, pp. 717–727, 2006.

[17] N. U. Lin and E. P. Winer, "New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors," Breast Cancer Research, vol. 6, no. 5, p. 204, 2004.

[18] J. W. Park, M. C. Liu, D. Yee et al., "Adaptive randomization of neratinib in early breast cancer," New England Journal of Medicine, vol. 375, no. 1, pp. 11–22, 2016.

[19] J. Veeraraghavan, C. De Angelis, R. Mao et al., "A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer," Annals of Oncology, vol. 30, no. 6, pp. 927–933, 2019.
[20] H. K. Kim, K. H. Park, Y. Kim et al., “Discordance of the PAM50 intrinsic subtypes compared with immunohistochemistry-based surrogate in breast cancer patients: potential implication of genomic alterations of discordance,” Cancer Research and Treatment, vol. 51, no. 2, pp. 737–747, 2019.

[21] C. Denkert, S. Loibl, A. Noske et al., “Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 105–113, 2010.

[22] R. Salgado, C. Denkert, C. Campbell et al., “Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab,” JAMA Oncology, vol. 1, no. 4, pp. 448–454, 2015.

[23] M. Ignatiadis, G. Van den Eynden, S. Roberto et al., “Tumor-infiltrating lymphocytes in patients receiving trastuzumab/ pertuzumab-based chemotherapy; a TRYPHAENA sub-study,” JNIC: Journal of the National Cancer Institute, vol. 111, no. 1, pp. 69–77, 2018.

[24] L. Gianni, T. Pienkowski, Y.-H. Im et al., “5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial,” The Lancet Oncology, vol. 17, no. 6, pp. 791–800, 2016.

[25] J. Baselga, I. Bradbury, H. Eitdman et al., “Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo-ALTTO): a randomised, open-label, multicentre, phase 3 trial,” The Lancet, vol. 379, no. 9816, pp. 633–640, 2012.

[26] G. von Minckwitz, M. Procter, E. de Azambuja et al., “Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer,” New England Journal of Medicine, vol. 377, no. 2, pp. 122–131, 2017.

[27] National Comprehensive Cancer Network, Breast Cancer NCCN Clinical Practice Guidelines in Oncology, National Comprehensive Cancer Network, Plymouth Meeting, PA, USA, 2018.

[28] M. Piccart-Gebhart, E. Holmes, J. Baselga et al., “Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial,” Journal of Clinical Oncology, vol. 34, no. 10, pp. 1034–1042, 2016.

[29] J. P. Higgins, Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons, Hoboken, NJ, USA, 2010.

[30] C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994.

[31] E. de Azambuja, A. P. Holmes, M. Piccart-Gebhart et al., “Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response,” The Lancet Oncology, vol. 15, no. 10, pp. 1137–1146, 2014.

[32] L. A. Carey, D. A. Berry, C. T. Cirrincione et al., “Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomised phase III trial of paclitaxel plus trastuzumab with or without lapatinib,” Journal of Clinical Oncology, vol. 34, no. 6, pp. 542–549, 2016.

[33] V. Guarneri, A. Frassoldati, A. Bottini et al., “Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1989–1995, 2012.

[34] V. Guarneri, M. V. Dieci, A. Frassoldati et al., “Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer,” The Oncologist, vol. 20, no. 9, pp. 1001–1010, 2015.

[35] F. A. Holmes, V. Espina, L. A. Liotta et al., “Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling,” BMC Research Notes, vol. 6, no. 1, p. 507, 2013.

[36] A. Robidoux, G. Tang, P. Rastogi et al., “Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 14, no. 12, pp. 1183–1192, 2013.

[37] A. Robidoux, G. Tang, P. Rastogi et al., “Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41,” Journal of Clinical Oncology, vol. 34, 2017.

[38] H. Bonnefoi, W. Jacot, M. Saghatchian et al., “Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study,” Annals of Oncology, vol. 26, no. 2, pp. 325–332, 2015.

[39] L. Gianni, T. Pienkowski, Y.-H. Im et al., “Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial,” The Lancet Oncology, vol. 13, no. 1, pp. 25–32, 2012.

[40] A. Moreno-Aspitia, E. M. C. Holmes, C. Jackisch et al., “Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L→T) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer,” Journal of Clinical Oncology, 2017.

[41] A. Chan, S. Delalorge, F. A. Holmes et al., “Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 17, no. 3, pp. 367–377, 2016.

[42] M. Martin, F. A. Holmes, B. Ejlertsen et al., “Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 18, no. 12, pp. 1688–1700, 2017.

[43] A. Nagayama, T. Hayashida, H. Jinno et al., “Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis,” JNCI: Journal of the National Cancer Institute, vol. 106, no. 9, 2014.

[44] M. Clavarezza, M. Puntoni, A. Gennari et al., “Dual block with lapatinib and trastuzumab versus single-agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials,” Clinical Cancer Research, vol. 22, no. 18, pp. 4594–4603, 2016.

[45] A. Nakashoji, T. Hayashida, T. Yokoe et al., “The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer,” Cancer Treatment Reviews, vol. 62, pp. 9–17, 2018.
[46] E. Bria, L. Carbognin, J. Furlanetto et al., “Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: sensitivity analysis of randomized trials,” Cancer Treatment Reviews, vol. 40, no. 7, pp. 847–856, 2014.

[47] L. Chen, W. Zhou, X. Hu, M. Yi, C. Ye, and G. Yao, “Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: a meta-analysis of randomized controlled trials,” Cancer Treatment Reviews, vol. 75, pp. 12–19, 2019.

[48] S. T. Brookes, E. Whitely, M. Egger, G. D. Smith, P. A. Mulheran, and T. J. Peters, “Subgroup analyses in randomized trials: risks of subgroup-specific analyses: power and sample size for the interaction test,” Journal of Clinical Epidemiology, vol. 57, no. 3, pp. 229–236, 2004.

[49] L. De Mattos-Arruda, R. Shen, J. S. Reis-Filho, and J. Cortés, “Translating neoadjuvant therapy into survival benefits: one size does not fit all,” Nature Reviews Clinical Oncology, vol. 13, no. 9, pp. 566–579, 2016.

[50] D. N. Amin, N. Sergina, D. Ahuja et al., “Resiliency and vulnerability in the HER2-HER3 tumorigenic driver,” Science Translational Medicine, vol. 2, no. 16, p. 16ra7, 2010.

[51] A. J. Chien, P. N. Munster, M. E. Melisko et al., “Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer,” Journal of Clinical Oncology, vol. 32, no. 14, pp. 1472–1479, 2014.

[52] G. Bianchini, “Is trastuzumab as a single agent obsolete in early breast cancer? No,” The Breast, vol. 43, pp. 142–145, 2019.

[53] M. Debiasi, C. A. Polanczyk, P. Ziegelmann et al., “Efficacy of anti-HER2 agents in combination with adjuvant or neoadjuvant chemotherapy for early and locally advanced HER2-positive breast cancer patients: a network meta-analysis,” Frontiers in Oncology, vol. 8, p. 156, 2018.

[54] A. Valachis, A. Nearchou, P. Lind, and D. Mauri, “Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence,” Breast Cancer Research and Treatment, vol. 135, no. 3, pp. 655–662, 2012.

[55] Y. Xin, W. W. Guo, Q. Huang et al., “Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials,” Cancer Medicine, vol. 5, no. 12, pp. 3454–3463, 2016.